Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
Sumali noong Mayo 2012
5 Larawan o video Mga larawan at video

Mga Tweet

Binlock mo si @AblynxABLX

Sigurado ka bang gusto mong tingnan ang mga Tweet na ito? Hindi maa-unblock ng pagtingin ang mga Tweet ni @AblynxABLX

  1. Ni-retweet ni
    Hul 26

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 retweet 4 (na) gusto
  2. Ni-retweet ni
    Hul 20

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 retweet 7 gusto
  3. Hul 20

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    1 sagot 9 mga retweet 14 (na) gusto
  4. Hun 27

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 retweet 16 (na) gusto
  5. Hun 26

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 mga retweet 6 (na) gusto
  6. May 29

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 retweet 9 (na) gusto
  7. May 22

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 retweet 12 gusto
  8. May 18

    Meet our experts and recruiters (booth 99) @

    2 gusto
  9. May 11

    Ablynx zit op schema via

    4 mga retweet 6 (na) gusto
  10. May 11

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 mga retweet 4 (na) gusto
  11. May 10

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 retweet 7 gusto
  12. May 2

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 retweet 6 (na) gusto
  13. Abr 7

    Annual Report 2016 is available online - view via

    1 retweet 4 (na) gusto
  14. Abr 7

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    1 retweet 4 (na) gusto
  15. Ni-retweet ni
    Mar 6

    Compelling data for developed psoriasis nanobody in collaboration

    3 retweet 2 gusto
  16. Ni-retweet ni
    Peb 28

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 sagot 51 retweet 103 gusto
  17. Ni-retweet ni
    Peb 24

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    1 retweet 1 gusto
  18. Peb 23

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 mga retweet 3 gusto
  19. Peb 9

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 retweet 2 gusto
  20. Peb 6

    Ablynx files caplacizumab for ultra rare blood disorder
    6 mga retweet 9 (na) gusto

Hindi pa nagtu-Tweet si:@AblynxABLX.

Ang paglo-load ay mukhang natatagalan.

Maaaring lumagpas na sa kapasidad ang Twitter o nakakaranas ng panandaliang problema. Subukan muli o bisitahin ang Twitter Status para sa karagdagang impormasyon.

    Maaari mo ring magustuhan

    ·